Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Formative Research

Date Submitted: Feb 29, 2024
Open Peer Review Period: Mar 1, 2024 - Apr 26, 2024
Date Accepted: Sep 6, 2024
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Developing the MyCancerGene Digital Health Portal to Improve Patients’ Understanding of Germline Cancer Genetic Test Results: Development, User, and Usability Testing Study

Triue P, Fetzer D, McLeod B, Schweickert K, Gutstein L, Egleston B, Domchek S, Fleisher L, Wagner LI, Wen KY, Cacioppo C, Ebrahimzadeh JE, Falcone D, Langer C, McCarty-Wood E, Karpink K, Posen S, Selmani E, Bradbury A

Developing the MyCancerGene Digital Health Portal to Improve Patients’ Understanding of Germline Cancer Genetic Test Results: Development, User, and Usability Testing Study

JMIR Form Res 2025;9:e56282

DOI: 10.2196/56282

PMID: 40366732

PMCID: 12120370

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Development, user and usability testing of MyCancerGene: A digital genetic health portal for patients who have received germline cancer genetic test results

  • Phillip Triue; 
  • Dominique Fetzer; 
  • Briana McLeod; 
  • Kathryn Schweickert; 
  • Lauren Gutstein; 
  • Brian Egleston; 
  • Susan Domchek; 
  • Linda Fleisher; 
  • Lynne I. Wagner; 
  • Kuang-Yi Wen; 
  • Cara Cacioppo; 
  • Jessica E Ebrahimzadeh; 
  • Dana Falcone; 
  • Claire Langer; 
  • Elisabeth McCarty-Wood; 
  • Kelsey Karpink; 
  • Shelby Posen; 
  • Enida Selmani; 
  • Angela Bradbury

ABSTRACT

Background:

The use of multigene panels in clinical practice has created an increasing likelihood that cancer genetic testing will leave many patients with uncertainties regarding test interpretation, implications and recommendations, which will change over time. We lack effective longitudinal clinical care models to provide updated information to patients regarding genetic test results or medical recommendations and to obtain personal and medical history updates.

Objective:

To bridge this gap in genetic medicine, we developed a patient and provider informed digital genetic health portal, "MyCancerGene," to improve longitudinal patient understanding and responses to genetic testing, especially in an evolving landscape of evidence and risk information.

Methods:

We used a 5-step process to develop the MyCancerGene digital tool. To better understand interest in and willingness to utilize a digital genetic health portal, we first surveyed 307 patients who completed genetic testing (Step 1). We completed qualitative interviews with 10 patients and a focus group with 17 providers to inform the content and function of MyCancerGene (Step 2). Next, we developed initial intervention content (Step 3) and completed user testing of intervention content with 25 providers and 28 patients (Step 4). After the prototype intervention was developed, we completed usability testing with eight patients for feedback on the final content, functions and ease of use (Step 5).

Results:

Patient and provider interviews identified high interest in a patient-centered digital genetic health portal to support longitudinal care. Potential advantages of MyCancerGene, according to patients and providers, included: increased accessibility, convenience and efficiency of accessing their genetic reports and documentation, and increasing and maintaining patient understanding through patient-centered content and educational resources. Both patients and providers endorsed the benefit of the tool for updating personal and family history and for providers to share new risk information, test interpretation or other medical changes. Patient and provider input informed eight key components of the tool: Landing Page, Summary of Care, My Genetic Test Results, My Family History, Provide an Update, Review an Update, Resources and a Screenings Tracker. They also recommended key functions, including the ability to download and print materials and the inclusion of reminders and engagement functions. Potential challenges identified included privacy/security concerns, the potential for electronic information to generate distress, and the need to integrate with existing health portals. While patients were comfortable with updates (even variant reclassification upgrades or clinically significant results), genetic providers had mixed feelings on the appropriateness of sharing variant reclassification upgrades through MyCancerGene

Conclusions:

MyCancerGene, a patient-centered digital genetic health portal, was developed with extensive patient and provider feedback and designed to enhance longitudinal patient understanding of and affective and behavioral responses to genetic testing, particularly in the era of evolving evidence and risk information. Clinical Trial: NCT04774445


 Citation

Please cite as:

Triue P, Fetzer D, McLeod B, Schweickert K, Gutstein L, Egleston B, Domchek S, Fleisher L, Wagner LI, Wen KY, Cacioppo C, Ebrahimzadeh JE, Falcone D, Langer C, McCarty-Wood E, Karpink K, Posen S, Selmani E, Bradbury A

Developing the MyCancerGene Digital Health Portal to Improve Patients’ Understanding of Germline Cancer Genetic Test Results: Development, User, and Usability Testing Study

JMIR Form Res 2025;9:e56282

DOI: 10.2196/56282

PMID: 40366732

PMCID: 12120370

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.